Inhibition of this microRNA is implicated in decreased hepatic steatosis, plasma cholesterol84 and also results in decreased circulatory lipoprotein levels through reduction of very low density lipoprotein (VLDL) secretion.85 Moreover, miR-223 controls cholesterol biosynthesis and high density lipoprotein (HDL) uptake in the liver.86 MiR-33b and miR-33a via SREBF1 and 2, respectively87,88 and miR-29 through regulation of Ahr and Sirt1 impact on cholesterol and lipoprotein metabolism.89 Additionally, MiR-181a improves hepatocyte insulin sensitivity via down-regulation of Sirt1.90 Here, SIRT1 is linked to fatty liver disease.